| Name | Title | Contact Details |
|---|
We are an OEM manufacturer of linear actuators and lifting columns, located in the Greater Grand Rapids area! Our parents company, Jiecang Linear Motion Technology Co.,Ltd was established in 2000 in Xinchang, China. Due to their high standards, their products quickly became globally respected for use in medical and home care equipment. With a large customer base in the United States, they found it necessary to purchase a facility locally which happened in 2018.
Qualitas is a full-service consulting firm dedicated to quality results for our clients. We provide expert advice and technical support for business processes and tools, especially Contract Lifecycle Management (CLM) and Enterprise Legal Management (ELM) solutions. We are passionate about helping our clients achieve long‑lasting success, and we are proud to be a woman-owned business.
Bradesco Bank is a Member FDIC Equal Housing Lender. With over 50 years of experience catering to the financial needs of individual, corporate and institutional customers, our products and services have been carefully structured to serve the domestic and international markets, which, combined with our personalized service, ensures that your experience with Bradesco Bank will be unparalleled. For more information, please access: http://www.bradescobank.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.